1. Home
  2. LICN vs LUNG Comparison

LICN vs LUNG Comparison

Compare LICN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lichen China Limited

LICN

Lichen China Limited

HOLD

Current Price

$5.93

Market Cap

88.1M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.15

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LICN
LUNG
Founded
2004
1995
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.1M
72.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
LICN
LUNG
Price
$5.93
$1.15
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
28.7K
721.1K
Earning Date
04-30-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$2.57
$1.23
52 Week High
$8.28
$7.05

Technical Indicators

Market Signals
Indicator
LICN
LUNG
Relative Strength Index (RSI) 86.23 30.99
Support Level $3.95 N/A
Resistance Level $6.80 $1.93
Average True Range (ATR) 0.50 0.11
MACD 0.28 -0.05
Stochastic Oscillator 91.02 1.65

Price Performance

Historical Comparison
LICN
LUNG

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: